ESTUTC-5 New YorkLog in Sign up

NAMS
NewAmsterdam Pharma Company N.V.
stockNASDAQ

At CloseNov 6, 2026 3:59:59 PM EST

18.89USD0.000%(-0.00)1,705,174

Pre-marketNov 6, 2026 8:52:30 AM EST

19.25USD+1.906%(+0.36)

After-hoursNov 6, 2026 4:27:30 PM EST

18.90USD+0.053%(+0.01)

16.23Bid18.91Ask2.68Spread

NAMS News

Day breaks

04:01 PM ESTNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ·

GlobeNewswire Inc.

05:04 PM ESTNAMS Maintained by Needham -- Price Target Lowered to $46.00 ·

GuruFocus

01:59 AM ESTNewAmsterdam Pharma (NAMS) Q3 Earnings Beat Expectations with Revenue Surge ·

GuruFocus

12:30 AM ESTNewAmsterdam Pharma GAAP EPS of -$0.14 beats by $0.30, revenue of $19.16M beats by $4.11M ·

Seeking Alpha

12:05 AM ESTNAMS SWOT Analysis: Key Insights from 10-Q Filing ·

GuruFocus

07:30 AM ESTNewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results ·

GlobeNewswire Inc.

08:00 AM ESTNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in November ·

GlobeNewswire Inc.

09:35 AM EDTSeeking Alpha’s Quant Spotlight: Highest and lowest rated healthcare stocks ahead of Q3 ·

Seeking Alpha

04:01 PM EDTNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ·

GlobeNewswire Inc.

08:00 AM EDTNewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease ·

GlobeNewswire Inc.

09:20 PM EDTNewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties? ·

Insider Monkey

09:00 AM EDTNewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) ·

GlobeNewswire Inc.